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Abstract
Background: Recent clinical studies point to rapid and sustained clinical, cognitive, and behavioral
improvement in both Alzheimer's disease and primary progressive aphasia following weekly
perispinal administration of etanercept, a TNF-alpha inhibitor that acts by blocking the binding of
this cytokine to its receptors. This outcome is concordant with recent basic science studies
suggesting that TNF-alpha functions in vivo as a gliotransmitter that regulates synaptic function in
the brain. We hypothesized that perispinal etanercept had the potential to improve verbal function
in Alzheimer's disease, so we included several standarized measures of verbal ability to evaluate
language skills in a clinical trial of perispinal etanercept for Alzheimer's disease.
Methods: This was a prospective, single-center, open-label, pilot study, in which 12 patients with
mild-to-severe Alzheimer's disease were administered etanercept, 25–50 mg, weekly by perispinal
administration for six months. Two additional case studies are presented.
Results: Two-tailed, paired t-tests were conducted comparing baseline performance to 6-month
performance on all neuropsychological measures. Test batteries included the California Verbal
Learning Test-Second Edition, Adult Version; Logical Memory I and II(WMS-LM-II) from the
Wechsler Memory Scale-Abbreviated; the Comprehensive Trail Making Test (TMT); Boston
Naming Test; and letter(FAS) and category verbal fluency. All measures revealed a significant effect
except for the Boston Naming Test and the TMT-4, with WMS-LM-II being marginally significant at
p = .05. The FAS test for letter fluency was most highly significant with a p < 0.0007. In addition,
rapid improvement in verbal fluency and aphasia in two patients with dementia, beginning minutes
after perispinal etanercept administration, is documented.
Conclusion: In combination with the previously reported results of perispinal etanercept in
Alzheimer's disease and primary progressive aphasia, these results further argue that larger scale
studies of this therapeutic intervention, including Phase 3 trials, are warranted in dementias. In
addition, these results may provide insight into the basic pathophysiologic mechanisms underlying
Alzheimer's disease and related forms of dementia, and suggest the existence of novel, rapidly
reversible, TNF-mediated pathophysiologic mechanisms in Alzheimer's disease which are worthy
of further investigation.
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Background
Substantial and increasing clinical, genetic, epidemio-
logic, and basic science evidence supports a central role of
excess tumor necrosis factor-alpha (TNF-alpha) in the
pathogenesis of Alzheimer's disease, suggesting that
excess TNF-alpha is a therapeutic target [1-19].
Etanercept, a recombinant dimeric fusion protein consist-
ing of the extracellular ligand-binding portions of two
human p75 TNF-alpha receptors linked to the Fc fragment
of human IgG1, binds to TNF-alpha and blocks its inter-
action with cell surface TNF-alpha receptors, thereby
reducing the biologic effect of excess TNF-alpha [20]. The
increasing evidence supporting a central role of TNF-alpha
in Alzheimer's suggested that, if appropriately adminis-
tered, etanercept, already FDA-approved for certain
inflammatory conditions mediated by TNF-alpha, such as
rheumatoid arthritis, might be efficacious in Alzheimer's.
In addition, in contrast to anti-TNF monoclonal antibod-
ies, such as infliximab, etanercept also binds to and sup-
presses the action of lymphotoxin (formerly known as
TNF-beta), the physiologic significance of which in Alzhe-
imer's is not presently known [21,22].
Perispinal administration of etanercept had been previ-
ously reported to be rapidly effective(within minutes) in
providing relief of intractable pain associated with lumbar
and cervical radiculopathy [23-26]. These findings, which
were consistent with the idea that perispinal administra-
tion enabled etanercept to cross the blood-dural barrier,
led to the expanded concept of the potential of the bi-
directional cerebrospinal venous system as a route of
delivery of therapeutic molecules to both the spine and
the brain [1-3,23-27]. Specifically, it was conceived that
etanercept, and potentially other large molecules, could
be delivered to the brain by perispinal administration and
subsequent retrograde carriage to the brain via the cere-
brospinal venous system [1-3,25,27].
In 2006, the authors and their colleagues published an
IRB-approved six month pilot study involving a cohort of
15 patients, that provided proof-of-concept that perispi-
nal delivery of etanercept was effective for the treatment of
Alzheimer's disease [2]. Clinical experience suggesting
continued clinical effectiveness with maintenance treat-
ment, continuing for more than two years in some
patients, was reported in 2007 [1]. Most recently, rapid
clinical, cognitive, and behavioral improvement, begin-
ning within minutes of administration of perispinal
etanercept, was documented in a patient with moderate
dementia fulfilling the criteria for probable Alzheimer's
[3].
Improved verbal abilities following perispinal etanercept
was reported in some of the above studies [1-3]. This
paper provides additional clinical data relevant to these
reports, in patients with Alzheimer's disease, and in a
related form of dementia in which patients present with
prominent effects on verbal function, semantic dementia.
An article by one of the authors documenting rapid
improvement following perispinal etanercept in another
form of dementia with prominent language dysfunction,
primary progressive aphasia, has just published [28].
Semantic dementia, discussed in the first case report
included, is considered by many to be a variant of fronto-
temporal dementia [29]. As with primary progressive
dementia, semantic dementia is a progressive neurode-
generative disorder for which there is no established treat-
ment. Excess TNF-alpha in the cerebrospinal fluid has
been documented not only in Alzheimer's disease, but
also in frontotemporal dementia and vascular dementia,
so that all of these may be included in the category of TNF-
alpha-mediated dementias [30,31].
Clinical data
The clinical data included in this article is separated into
two sections. In the first section, new data related to verbal
function from an IRB-approved Phase 2 clinical research
study involving a 15 patient cohort with Alzheimer's dis-
ease ranging in severity from mild to severe is reported.
This data supplements a previous report of improvement
in standard cognitive measures in this same 15 patient
cohort which has been previously published [2]. The full
methodology of this clinical trial utilizing perispinal
etanercept has been previously reported [2].
In the second section case reports from two additional
patients are included. These patients were not research
subjects, but rather were treated with perispinal etanercept
off-label as part of our usual practice of medicine.
Clinical trial data
Methods
This IRB-approved clinical trial was performed prior to,
and independent of, the two case reports described below.
The methodology of this clinical trial has been previously
reported [2].
The patient and the patient's son gave full consent to be
identified in the video which accompanies this article and
for the video's publication.
Briefly, the author and his colleagues designed and carried
out an open-label, prospective, single-center, open-label,
pilot (proof-of-concept) study of 15 patients with proba-
ble Alzheimer's disease ranging in severity from mild to
severe treated weekly with perispinal etanercept for a
period of six months [2]. This clinical trial began in 2004
after institutional review board approval was obtainedBMC Neurology 2008, 8:27 http://www.biomedcentral.com/1471-2377/8/27
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[2]. The study was also registered in the clinical trial data-
base maintained by the National Institute of Health
(NCT00203359). Improvement in the main outcome
measures, which were the Mini-Mental State Examination
(MMSE) [32], the Alzheimer's Disease Assessment Scale-
Cognitive subscale (ADAS-Cog) [33], and the Severe
Impairment Battery [34], has been previously reported
[2].
During the 15 patient pilot study, in addition to the stand-
ard cognitive measures above, additional neuropsycho-
logical test batteries were administered, many of which
carefully measure verbal function. The test batteries used
included the California Verbal Learning Test-Second Edi-
tion, Adult Version (CVLT-II) [35], Logical Memory I
(LMI), and II (LMII) from the Wechsler Memory Scale-
Abbreviated (WMS-a) [36], the Comprehensive Trail Mak-
ing Test (TMT) [37,38], Boston Naming Test [39], and let-
ter(FAS) and category verbal fluency [40-42].
Neurocognitive assessments were conducted monthly.
Three of the 15 patients in the pilot study with severe
dementia were excluded as they could not be reliably
assessed with these tools.
Results
Two-tailed, paired t-tests were conducted comparing base-
line performance to 6-month performance on all neu-
ropsychological measures. T-tests were conducted
comparing baseline assessment scores to 6-month assess-
ment scores. Standard T scores were used in the CVLT-II
1–5, TMT, and Verbal Fluency analyses, and standard z-
scores were used for WMSa, and secondary CVLT-II meas-
ures analyses, while raw values were used for the Boston
Naming Test. As can be seen from the figure (Figure 1), all
measures revealed a significant effect except for the Boston
Naming Test and the TMT-4, with WMS-LM-II being mar-
ginally significant at p = .05. The FAS test for letter fluency
[40-42] was most highly significant with a p < 0.0007.
Case Reports
Case report one, Progressive Aphasia, Semantic Dementia
The patient is a 78 y.o. man with a six year history of pro-
gressive dementia beginning with forgetfulness, followed
by progressive paucity of speech and associated language
difficulties. Three years before he began speaking with
predominantly one word answers to questions. In July
2005 he had a neuropsychological evaluation which dem-
onstrated a variety of language difficulties, with parapha-
sic errors with word substitutions and mispronunciations.
There were obvious impairments in attention, linguistic
processing, and memory. He had dysnomia, oral fluency
problems, and articulation difficulties. In September
2005, it was noted that he began using word substitu-
tions, such as "hotto" for "honda", "tea" for "tie", and
"burgle" for "verbal". There were no changes in mood,
personality, or behavior, and no depression, hallucina-
tions, or delusions. In April 2006, he was evaluated by a
local neurologist and found to have severe aphasia. Work-
up included an MRI, which showed global volume loss
and minimal small vessel occlusive disease. CBC, RPR,
B12, folate and TSH were normal. A diagnosis of possible
primary progressive aphasia was made. Memantine was
begun. A second opinion from another neurologist was
obtained on April 25, 2006. His MMSE was 12/30. There
was severe aphasia and word-finding difficulty and
severely impaired comprehension, naming and word rep-
etition. A diagnosis of semantic dementia, a language var-
iant of frontotemporal dementia [29,43], was made.
Memantine was increased to 10 mg twice a day, but
caused constipation and was discontinued. In May 2006,
donepezil was begun at 5 mg per day and increased to 10
mg daily the following month. By September 2006, the
patient's memory difficulties had progressed such that he
could not remember events from the same day. His speech
was limited to only a few single words. Memantine was re-
started. By February 2007, he was having difficulties per-
forming the normal activities of daily living. He required
assistance with showering, and on examination was
almost mute. By May 2007, his comprehension of spoken
commands had worsened, accompanied by marked apa-
Changes in verbal fluency, learning, and memory over 6  months during maintenance treatment with perispinal  etanercept in a 12 subject pilot study, as reflected by T-score  change from baseline to 6 months Figure 1
Changes in verbal fluency, learning, and memory 
over 6 months during maintenance treatment with 
perispinal etanercept in a 12 subject pilot study, as 
reflected by T-score change from baseline to 6 
months. Two-tailed, paired t-tests were conducted com-
paring baseline performance to 6-month performance on all 
neuropsychological measures. Abbreviations: California Ver-
bal Learning Test-Second Edition, Adult Version (CVLT-II), 
including tests 1–5 and slope of change; Logical Memory I 
(LMI), and II (LMII) from the Wechsler Memory Scale-Abbre-
viated (WMS-a); the Comprehensive Trail Making Test 
(TMT), including tests 1 (TMT-1) and 4 (more difficult) 
(TMT-4); Boston Naming Test; and letter(FAS) and cate-
gory(animal) verbal fluency.BMC Neurology 2008, 8:27 http://www.biomedcentral.com/1471-2377/8/27
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thy. Memantine was discontinued because of excessive
daytime somnolence.
On February 6, 2008, the patient was brought to our clinic
for evaluation. He had been mostly mute for more than
four months. There was no history of head trauma,
tremor, or significant active medical illness. The family
specifically denied a history of demyelinating disease,
congestive heart failure, bleeding disorder, diabetes melli-
tus, lymphoma, blood disorder, hepatitis, immunosup-
pression, or exposure to tuberculosis. There was a
previous history of disc surgery in 1997. Present medica-
tions were donepezil 5 mg per day and memantine 10 mg
twice a day. The patient's neurological examination was
unremarkable except for the mental status exam. The
patient had no spontaneous speech, did not verbally
respond to most requests, and was unable to follow any
but the simplest commands. Laboratory examination was
unremarkable, with a normal CBC, serum folate, free T4
index, serum vitamin B12, creatinine, and hemoglobin
A1c. PPD skin testing for tuberculosis was negative.
After written informed consent was obtained, as part of
our usual practice of medicine, perispinal etanercept (25
mg) was administered by injection to the posterior neck in
the midline followed by Trendelenburg positioning, as
previously described [2]. Administration was tolerated
without difficulty. Ten minutes after injection the patient
was able to repeat single numbers, and was asked if he felt
better. He replied, "I don't know". The patient's son, who
spoke about his father's improvement that day and eight
days later (Additional file 1), commented that the
improved speech output following perispinal etanercept
was highly significant. The patient returned to our clinic
for follow-up on February 14 at which time his son
reported that his father was better in many ways. His
behavior was improved as was his ability to follow spoken
commands; his verbal output of intelligible words was
notably increased, although the words were few and usu-
ally single; and he was walking faster than he had been. At
one month the patient returned with his son who
reported that all of his previously reported clinical
improvement had been sustained for the entire month.
Case report two, non-fluent aphasia secondary to 
Alzheimer's disease
This 80 y.o. married, right-handed engineer presented to
our clinic with a two and one-half year history of increas-
ing word-finding difficulty, which had become much
more prominent in the past six months. This was accom-
panied by a less prominent disturbance of short-term
memory during the past six to twelve months. Also during
the past six months the wife reported gradual deteriora-
tion in his handwriting and increasing difficulty in hand-
writing notes. He continued driving to work. He remained
independent and able to perform all of the normal activi-
ties of daily living. No changes in personality were noted.
There was no history of hallucinations, motor symptoms,
seizures, or apathy.
Past medical history included pericarditis with possible
viral myocarditis, atrial fibrillation, benign prostatic
hypertrophy, hypothyroidism, and increased cholesterol.
There was no history of demyelinating disease, substance
abuse, congestive heart failure, bleeding disorder, diabe-
tes mellitus, lymphoma, blood disorder, hepatitis, immu-
nosuppression, or exposure to tuberculosis. Three years
before the patient had an automobile accident with a brief
loss of consciousness. Current medications were tamsu-
losin, dutasteride, diltiazem, donepezil, levothyroxine,
atorvastatin, and warfarin.
Laboratory testing was unremarkable, with normal white
blood cell count, hemoglobin 13.4, hematocrit 39.5,
platelets 275,000, INR 1.0, and normal serum chemis-
tries, BUN, serum vitamin B12 and folate, RPR, TSH and
T4, and chest x-ray. PPD skin testing for tuberculosis was
negative. Carotid duplex study on November 22, 2006
showed plaque formation in the bilateral carotid bifurca-
tion without any hemodynamically significant stenosis.
MRI of the brain had previously documented moderate
atrophy and nonspecific periventricular white matter
changes consistent with microvascular white matter
ischemic changes. FDG-PET of the brain on January 22,
2008 showed hypometabolism out of proportion to the
degree of atrophy in the left parietal and left temporal
regions (Figure 2). There was also hypometabolism of a
lesser degree including the left cingulate cortex and left
occipital region (Figure 2). These findings were read by
the neuroradiologist as most consistent with a primary
neurodegenerative process, probably asymmetric Alzhe-
imer's disease.
On examination, the patient's blood pressure was 135/77,
he was afebrile, with pulse 60 and irregularly irregular,
respiratory rate 12, and lungs clear to auscultation. He was
pleasant and cooperative, with obvious word-finding dif-
ficulty even in casual speech. His spontaneous and pri-
mary language was English. There was a prolonged latency
of verbal response to most questions, with obvious cir-
cumlocution with pronouns for noun substitution associ-
ated with mild anxiety. Affect seemed slightly flat.
He was oriented to the year and month but not the calen-
dar date, day of the week, city or location. On fund of
knowledge testing, he could name the present and prior
president of the U.S. but none past Clinton.
He had obvious impairment in naming common objects;
specifically he could not name a comb, coin, toothbrushBMC Neurology 2008, 8:27 http://www.biomedcentral.com/1471-2377/8/27
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or key. He could not identify pictures of a camel or rhinoc-
eros but could identify a lion. On the first 10 items of the
short form of the Boston Naming Test [39] he could only
identify correctly a house and bench; he used marked cir-
cumlocutions for the remainder of the items. He was able
to accurately state his birthplace, place of birth and age
and number of minutes in an hour but not the number of
days in a year. On a phonemic fluency test (FAS) [40-42]
he could name only three words beginning with the letter
S in 60 seconds prior to perispinal etanercept treatment.
On a semantic task for category fluency he could list only
three animals over 30 seconds.
He had marked difficulty with memory and took five rep-
etitions to register five memoranda, but could not retrieve
any of these memoranda after 90 seconds, despite categor-
ical cueing and multiple choice cueing. When asked to
recite the days of the week in reverse order starting with
Sunday he could only recite Sunday and Saturday.
Cranial nerves II through XII were intact. He had a normal
fundoscopic examination and visual fields were full to
confrontation.
Deep tendon reflexes were symmetrical, with supinator
and biceps two plus, triceps one plus, quadriceps one
plus, and absent ankle reflexes. Toe signs were flexor.
There was full strength throughout with normal station
and gait. There was no atrophy, fasciculations, or grasp-
ing. There was a positive palmomental reflex bilaterally.
There was a mild intention tremor, but no resting tremor,
rigidity, ataxia, or dystonia. Sensation was intact to pin-
prick and light touch throughout.
The patient had difficulty with mathematical calculations.
Prior to treatment he could not divide 58 by two and
could not add 29 plus 11. MMSE score was 18/30. Mon-
treal Cognitive Assessment score was 12/30 [44]. His Cog-
nitive Abilities Screening Instrument (CASI) [45] score
was 69.2, all consistent with moderate cortical dementia.
After written informed consent was obtained, he was
treated, as part of our usual practice of medicine, with per-
ispinal etanercept (25 mg) administered to the posterior
neck in the midline followed by Trendelenburg position-
ing. This was tolerated without difficulty.
Eight minutes after perispinal etanercept the patient was
re-examined. He seemed more alert. His speech seemed
less effortful. He could recite all seven days of the week
backwards, which he could not do before the treatment,
and correctly calculated 58 divided by two.
The patient and his wife flew home to New York. They
returned three weeks later, at which time the patient
received a second dose of perispinal etanercept 25 mg. The
wife reported that during the weeks following the first
dose, the patient was improved in his conversational abil-
ity, attention span, and forgetfulness. These improve-
ments were particularly noticeable in the first week after
treatment. No adverse effects of treatment were noted. On
examination the patient's verbal fluency was notably
improved, he spoke with greater ease, and with less
latency of response to questions. In casual conversation
he appeared to have less word-finding difficulty. Ten min-
utes after this second dose his speech appeared further
improved.
The patient and his wife again flew back to New York and
returned to California three weeks later. His wife reported
continued improvement, but again noted greater
improvement during the first week following the perispi-
nal etanercept dose. She reported improvement in his
ability to handwrite notes and conversational ability, as
well as some improvement in his organizational skills. In
addition, examination prior to his third dose of perispinal
etanercept revealed improvement in affect and attention.
His speech was clearly more fluent, and testing of his pho-
nemic fluency (FAS) for the letter S was notable (11 words
in 60 seconds) as it demonstrated a marked improvement
from his performance prior to his first perispinal etaner-
FDG-PET brain scan of a patient with non-fluent aphasia sec- ondary to Alzheimer's disease (case report 2), prior to treat- ment, demonstrating decreased glucose metabolism in the  left parietal, bilateral temporal, and left frontal lobe Figure 2
FDG-PET brain scan of a patient with non-fluent 
aphasia secondary to Alzheimer's disease (case 
report 2), prior to treatment, demonstrating 
decreased glucose metabolism in the left parietal, 
bilateral temporal, and left frontal lobe.BMC Neurology 2008, 8:27 http://www.biomedcentral.com/1471-2377/8/27
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cept treatment six weeks before. Although with some dif-
ficulty, he was also able to recite the days of the week in
reverse order, which he had not been able to do at all prior
to treatment. Montreal Cognitive Assessment score was
14/30 [44]. A third dose of perispinal etanercept 25 mg
was administered. Because the improvement was greatest
during the week following each of the two previous treat-
ments, the patient was advised to attempt weekly dosing.
Discussion
The data from this six month Phase 2 clinical trial in 12
patients with Alzheimer's disease suggest notable
improvements in verbal learning, memory, and fluency in
this cohort treated with perispinal etanercept. This data is
consistent with the preliminary evidence from the two
case reports included herein, and with the case study most
recently reported by the authors [3,4]. The data reported
here, along with confirmatory clinical experience of more
than three years duration in Alzheimer's disease, suggest
that perispinal etanercept treatment of patients with TNF-
alpha mediated dementias may result in improvement in
verbal fluency and related language functions [1-4]. In
addition, these data, combined with those from previous
reports, suggest that positive clinical effects may begin
rapidly, within minutes, and may be durable with ongo-
ing maintenance dosing [1-4]. Perispinal etanercept may
result in improvement in behavior, frontal lobe and exec-
utive function, conversational abilities, naming abilities,
and ability to comprehend and follow spoken commands
[1-4]. The clinical effects suggest that this treatment
approach, in addition to its utility for other forms of
Alzheimer's disease, may be useful for patients with fron-
totemporal dementia and frontal variant Alzheimer's dis-
ease [46]. Further study will be necessary to characterize
response rates, dosing schedules, and duration of
response in the non-Alzheimer dementias.
The family and clinician observations of improvements in
the patients' cognition, verbal ability, and behavior, sug-
gest the possibility that perispinal etanercept may have
the ability to reduce the caregiver burden in selected
patients with severe dementia. One may argue that these
are observations in only a small number of patients. But
rather than dismissing the potential scientific significance
of these observations, it would be more scientifically
appropriate to view these results as observations which
merit further investigation [47]. Small studies and case
reports lend themselves to examination of individual
treatment responses, particularly with diseases which are
well-studied and characterized [47]. In a study such as
this, the first objective is often to establish the likelihood
of a biological effect beyond the chance of a type I error,
i.e., whether any individual experienced a significant
treatment effect [47]. Further study will be necessary to
characterize response rates, dosing schedules, and dura-
tion of response.
As previously hypothesized, the current results suggest
that perispinal etanercept may have the ability to influ-
ence brain function, perhaps through delivery via the cer-
ebrospinal venous system [1,3,25]. This form of delivery
may be facilitated by the large surface area of the choroid
plexus (which may be as much as one-half the size of the
entire surface area of the cerebral capillaries) and by the
decreased barrier characteristics of the choroid plexus
[48,49]. Etanercept reaching the choroid plexus could
have widespread neuronal effects due to its effect on glia,
even in the absence of deeper brain delivery, due to the
widespread effects exerted on the multiple synapses even
a single glial cell can control, through their extensive pro-
jections [3,50-52].
As previously discussed, the rapid clinical improvements
seen following perispinal etanercept may be due to synap-
tic effects related to the role of TNF-alpha as a gliotrans-
mitter [3,50-52]. Other molecules which function as
gliotransmitters are adenosine, glutamate, ATP, and D-
serine [50-52]. Because of the related pro-inflammatory
effects of TNF-alpha and IL-1, initially one might be
tempted to speculate that IL-1 might have synaptic effects
similar to those of TNF-alpha. Caution, however, may be
in order, because these cytokines may have quite diver-
gent clinical effects [53]. Indeed, it is quite likely that the
effects of different cytokines may vary across the different
dementias, and even within the spectrum of diseases
which we currently classify together as different forms of
Alzheimer's disease [54].
In addition to synaptic effects, etanercept may have vascu-
lar effects which may contribute to both the rapid and sus-
tained clinical improvement noted. Etanercept may have
the potential to improve endothelial dysfunction and
thereby have a vasculoprotective role [8]. In addition,
etanercept may have the potential to improve microvascu-
lar function, particularly in a clinical disorder associated
with TNF excess [55]. This may be of particular impor-
tance in patients treated with perispinal etanercept who
have a vascular component to their dementia, such as
patients with mixed dementia consisting of Alzheimer's
disease and vascular dementia.
Anatomically targeted delivery of etanercept, tailored to
the disease target, may be critically important to ensure
the success of the intervention [1,2,23-25,56-58]. Delivery
of etanercept into an anatomic structure where it would
not have access to the primary site of pathology, such as
intradiscal administration for treatment of radiculopathy,
may doom such an intervention to failure [57]. This high-
lights the concern of the authors that physicians inexperi-BMC Neurology 2008, 8:27 http://www.biomedcentral.com/1471-2377/8/27
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enced with perispinal administration of etanercept may
attempt to initiate etanercept treatment in patients with
dementia utilizing the routes normally used to treat rheu-
matoid arthritis and psoriasis patients i.e. subcutaneous
administration in the abdomen, arms, or thighs. Pub-
lished data do not support the concept that etanercept can
reach the cerebrospinal fluid in therapeutic concentration
if given by its usual method of subcutaneous administra-
tion in the abdomen [59,60]. Etanercept does not cross
the blood-brain barrier when administered systemically
[59]. Conversely, when delivered via perispinal adminis-
tration into Batson's plexus, large molecules may have the
ability to reach the brain via retrograde delivery through
the cerebrospinal venous system, a potential anatomic
route first demonstrated by Batson in cadavers [1,27,61].
In addition to concerns regarding drug delivery, dosage
and dosing intervals may need to be individualized for
each patient. This requires experience with the use of per-
ispinal etanercept in the treatment of patients with
dementia. Potential side effects of the use of perispinal
etanercept for the treatment of dementia, an off-label use,
include all of the risks inherent with the use of etanercept
for its labeled indications, which may include rare
instances of death, infection, decreased blood counts,
congestive heart failure, lymphoma, demyelinating dis-
ease, and reactivation of tuberculosis [62]. PPD skin test-
ing prior to initiation of etanercept treatment is
mandatory, and a black box warning highlighting the risk
of tuberculosis, sepsis, and severe infection has been
added to the package insert [62].
There are limitations to the data presented. The clinical
trial was open-label, and not controlled. The data is lim-
ited. These caveats notwithstanding, the scientific ration-
ale for the further investigation of anti-TNF-alpha
treatment of Alzheimer's disease is compelling, with sup-
porting genetic, epidemiologic, clinical, and basic science
evidence [1-19,30,50,52]. In addition, family members,
independent neurologists, and other independent observ-
ers have confirmed the clinical, cognitive, and behavioral
improvement noted [1-4]. Nevertheless there is, as yet, no
double-blind, placebo-controlled data, the availability of
which would further strengthen the reported results.
These additional clinical trial results in this 12 patient
cohort, together with these case study results, further sup-
port the initiation of larger scale studies of this therapeutic
intervention, including Phase 3 trials. In addition, these
results may provide insight into the basic pathophysio-
logic mechanisms underlying Alzheimer's disease and
related forms of dementia, and suggest the existence of
novel, rapidly reversible, TNF-mediated pathophysiologic
mechanisms in both Alzheimer's disease and semantic
dementia which are worthy of further investigation.
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